middle.news
Chimeric Therapeutics Advances CAR-T and NK Trials with Strong Safety Signals
5:02pm on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Advances CAR-T and NK Trials with Strong Safety Signals
5:02pm on Wednesday 29th of April, 2026 AEST
Key Points
CHM CDH17 trial reaches 450 million cell dose with no safety issues
CORE-NK Phase 1b trial hits 60% complete response in AML
CHM CLTX asset returned to City of Hope to focus resources
Board refreshed with Dr Bradley Glover as Chair and new CFO
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE